SVRA - חוב כולל להון Savara Pharma

The seamless operation of biotech plants is driving growth, as confirmed by the leverage ratio—the ratio of total debt to equity—which settled at 0.20. The foundation of Savara Inc. (SVRA) is based on partnerships with universities to develop Molgradex, the pricing power to independently determine the cost of therapy for rare lung pathologies, and the efficient utilization of cleanrooms.

The stability of Savara Inc. (SVRA) depends on the balance between investments in automated bioreactors and their financing costs. This ratio compares total liabilities to net assets, determining the degree of financial leverage. The metric measures the business's reliance on external borrowings relative to its equity. By analyzing the debt-to-equity ratio on GURU.Markets, an investor assesses liquidity risk. The trend of this indicator reflects either debt deleveraging or a reduction in the resource base.